How an engineered CD40 antibody, injected into tumors, builds the immune structures that drive whole-body cancer responses
Why intravenous oncolytic virus JX-594 lit up immune biomarkers but not tumor responses in HR+ breast cancer
Why IDO1 inhibitors fell short in cancer immunotherapy — and what comes next for tryptophan targeting
How CD95 keeps NF-κB switched off in triple-negative breast cancer — and what its loss unleashes
How CD95/Fas helps triple-negative breast cancer escape NK-cell control in preclinical models
How mature TLSs identify solid tumor patients more likely to benefit from PD-1 blockade
How plasma LIF predicts immune-checkpoint blockade resistance and a TLS-poor tumor microenvironment
Why IDO1 staining can miss L-kynurenine production in colorectal and breast tumors
